S
Hi,
I would greatly appreciate some advise on ISO 10993 complement System Testing (C3a and SC59-b). I understand that C3a is more difficult to detect (shortlived) and thus if I have a positive SC59-b with a negative C3a, I may still be considered potentially activating.
Does anyhow know how I can determine what an acceptable complement activation limit is? If a test device is only ~10% of the positive control (latex) in terms of SC59-b activation; yet significantly greater than the negative controls, how do I or the regulatory authorities (e.g., FDA) define the limit to when the test article is a complement system activator?
I have tried to look in the literature for some ideas but to no avail. Would be very grateful for some insights.
Thank you in advance
Karen
I would greatly appreciate some advise on ISO 10993 complement System Testing (C3a and SC59-b). I understand that C3a is more difficult to detect (shortlived) and thus if I have a positive SC59-b with a negative C3a, I may still be considered potentially activating.
Does anyhow know how I can determine what an acceptable complement activation limit is? If a test device is only ~10% of the positive control (latex) in terms of SC59-b activation; yet significantly greater than the negative controls, how do I or the regulatory authorities (e.g., FDA) define the limit to when the test article is a complement system activator?
I have tried to look in the literature for some ideas but to no avail. Would be very grateful for some insights.
Thank you in advance
Karen